A Phase 1/2 interventional study of VELCADE (bortezomib) and dexamethasone in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-26.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.
Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 24th largest by enrollment of the 167 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 1/2, and was the 37th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Northside Hospital, Inc. · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 116 · Phase 3 16
First in 1988; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 158 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 167 interventional studies. Of the 119 that completed or were terminated, 68 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 171 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
54 studies in Multiple Myeloma by Takeda: 2 open now, 4 under way, 1 of them phase 3. Of 47 finished, 33 (70%) have results posted.
Among the 54 studies in Multiple Myeloma by Takeda, this one is the 10th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2007, is one of 6 in phase 1/2, and was the 7th registered.
Takeda’s Multiple Myeloma studies by the year they started, since 2002.
8 of the studies testing cyclophosphamide in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909059Northside Hospital, Inc.CAR T-cell Therapy in Patients With Renal Dysfunction | 2026-12-31 |
| NCT04166565Stichting European Myeloma NetworkDaratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease | 2027-03 |
| NCT06623630Washington University School of MedicineLymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | 2027-06-30 |
| NCT05909826Dong-A University HospitalCarfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM | 2027-06-30 |
| NCT03710421City of Hope Medical CenterCS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | 2027-08-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 171 studies testing cyclophosphamide in Multiple Myeloma, from their registry updates:
Among Takeda’s 54 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with multiple myeloma who have received no prior treatment. This study will evaluate whether the addition of Revlimid to VELCADE and Dexamethasone will increase the complete response (CR)/ very good partial response (VGPR) rate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VELCADE (bortezomib), dexamethasone, and Revlimid (lenalidomide)
Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: Revlimid (lenalidomide)
VELCADE (bortezomib), dexamethasone, cyclophosphamide, Revlimid (lenalidomide)
Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: cyclophosphamide · Drug: Revlimid (lenalidomide)
VELCADE (bortezomib), dexamethasone, cyclophosphamide
Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: cyclophosphamide
Modified dosing of VELCADE (bortezomib), dexamethasone, cyclophosphamide
Drug: VELCADE (bortezomib) · Drug: dexamethasone · Drug: cyclophosphamide
bortezomib 1.3 mg/m\^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
cyclophosphamide 500 mg/m\^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm) lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)
Number of Patients With Combined Complete Response and Very Good Partial Response
Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very good partial response requires serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 h
Time frame: Up to 48 weeks or until disease progression
Number of Patients With Adverse Events (AEs)
Evaluate the safety and tolerability of the combination therapy
Time frame: From first dose of study drug through the 30 day post-treatment AE assessment visit
Number of Patients With Overall Response
Overall Response includes complete response and partial response. Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Partial response requires at least 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by at least 90% or to \< 200 mg per 24 hour.
Time frame: Up to 48 weeks or until disease progression
Number of Patients With Stringent Complete Response Rate
Stringent Complete Response is defined as complete response plus normal free light chain (kappa/lambda) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
Time frame: Up to 48 weeks or until disease progression
Number of Patients With Complete Response Rate + Near Complete Response Rate
Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Near Complete response requires positive immunofixation on the serum and/or urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow.
Time frame: Up to 48 weeks or until disease progression
Duration of Response
Duration of response is the time from date of first documented confirmed response to date of first documented progressive disease. A confirmed response is a response that has been observed on at least two consecutive assessments. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.
Time frame: Up to 48 weeks or until disease progression
Time to Disease Progression
Time to disease progression is defined as time from the date of randomization to the date of first documented progressive disease. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.
Time frame: Up to 48 weeks or until disease progression
Time to Response
Time to response is defined as time from date of randomization to the date of the first documentation of a confirmed response. confirmed response is a response that has been observed on at least two consecutive assessments.
Time frame: Up to 48 weeks or until disease response
Progression-free Survival
Progression-free survival is defined as time from the date of randomization to the date of the first documented progressive disease or death. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.
Time frame: Up to 48 weeks or until disease progression/death
Probability of 1-year Survival
Time frame: survival probability at 1 year after randomization
Overall Survival
Overall survival is defined as time from the date of randomization to the date of death
Time frame: Up to 48 weeks or until death
| Milestone | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Started | 42 | 66 | 33 | 17 |
| Completed | 26 | 39 | 18 | 12 |
| Not completed | 16 | 27 | 15 | 5 |
| Withdrew: Adverse event | 8 | 11 | 4 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
| Withdrew: Physician decision | 0 | 2 | 4 | 1 |
| Withdrew: Progressive disease | 2 | 4 | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 4 | 2 | 1 |
| Withdrew: Other | 2 | 5 | 2 | 2 |
Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Very good partial response requires serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \< 100 mg per 24 h
| participants | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Number of Patients With Combined Complete Response and Very Good Partial Response | 21 | 23 | 13 | 9 |
Evaluate the safety and tolerability of the combination therapy
| participants | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Number of Patients With Adverse Events (AEs) | 42 | 65 | 33 | 17 |
Overall Response includes complete response and partial response. Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Partial response requires at least 50% reduction of serum M-protein and reduction in 24-h urinary M-protein by at least 90% or to \< 200 mg per 24 hour.
| participants | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Number of Patients With Overall Response | 35 | 35 | 24 | 17 |
Stringent Complete Response is defined as complete response plus normal free light chain (kappa/lambda) ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.
| participants | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Number of Patients With Stringent Complete Response Rate | 7 | 6 | 3 | 5 |
Complete response requires negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow. Near Complete response requires positive immunofixation on the serum and/or urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow.
| participants | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Number of Patients With Complete Response Rate + Near Complete Response Rate | 17 | 14 | 10 | 8 |
Duration of response is the time from date of first documented confirmed response to date of first documented progressive disease. A confirmed response is a response that has been observed on at least two consecutive assessments. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.
| days | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Duration of Response | NA (302 to NA) | NA (583 to NA) | NA (NA to NA) | NA (NA to NA) |
Time to disease progression is defined as time from the date of randomization to the date of first documented progressive disease. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.
| days | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Time to Disease Progression | NA (NA to NA) | NA (631 to NA) | NA (NA to NA) | NA (NA to NA) |
Time to response is defined as time from date of randomization to the date of the first documentation of a confirmed response. confirmed response is a response that has been observed on at least two consecutive assessments.
| days | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Time to Response | 49 (43 to 175) | 50 (41 to 145) | 55 (42 to 302) | 49 (42 to 194) |
Progression-free survival is defined as time from the date of randomization to the date of the first documented progressive disease or death. Disease progression requires any one or more of the following: serum m-protein increase \>= 25% from nadir(absolute increase \>= 0.5 g/dL); Urine m-protein increase \>= 25% from nadir(absolute increase \>= 200 mg/24 hr), bone marrow plasma cell percentage increase \>= 25% from nadir(absolute increase \>= 10%), new bone lesion or soft tissue plasmacytomas.
| days | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Progression-free Survival | NA (356 to NA) | 631 (555 to NA) | NA (778 to NA) | NA (NA to NA) |
| percentage of patients | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Probability of 1-year Survival | 100 | 91.6 | 100 | 100 |
Overall survival is defined as time from the date of randomization to the date of death
| days | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| Overall Survival | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Collected over From first dose of any study drug to 30-day post-treatment adverse event assessment, up to 48 weeks and 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| V-DR | — | 17/42 (40.5%) | 41/42 (97.6%) |
| VDCR | — | 26/66 (39.4%) | 65/66 (98.5%) |
| V-DC | — | 7/33 (21.2%) | 33/33 (100%) |
| VDC-mod | — | 7/17 (41.2%) | 17/17 (100%) |
| Event | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| SyncopeNervous system disorders | 0/42 | 1/66 | 0/33 | 2/17 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/42 | 5/66 | 0/33 | 0/17 |
| Urinary tract infection NOSInfections and infestations | 0/42 | 0/66 | 2/33 | 0/17 |
| Hypotension NOSVascular disorders | 1/42 | 2/66 | 2/33 | 0/17 |
| Pneumonia NOSInfections and infestations | 2/42 | 3/66 | 0/33 | 1/17 |
| InfluenzaInfections and infestations | 0/42 | 0/66 | 0/33 | 1/17 |
| Pneumonia streptococcalInfections and infestations | 0/42 | 0/66 | 0/33 | 1/17 |
| Small intestinal obstruction NOSGastrointestinal disorders | 0/42 | 1/66 | 0/33 | 1/17 |
| PyrexiaGeneral disorders | 2/42 | 3/66 | 1/33 | 1/17 |
| WeaknessGeneral disorders | 0/42 | 0/66 | 0/33 | 1/17 |
| Event | V-DR | VDCR | V-DC | VDC-mod |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 26/42 | 29/66 | 16/33 | 7/17 |
| Peripheral neuropathy NOSNervous system disorders | 14/42 | 24/66 | 15/33 | 9/17 |
| NeutropeniaBlood and lymphatic system disorders | 8/42 | 33/66 | 17/33 | 8/17 |
| Pain in limbMusculoskeletal and connective tissue disorders | 12/42 | 22/66 | 12/33 | 7/17 |
| Peripheral sensory neuropathyNervous system disorders | 17/42 | 26/66 | 9/33 | 1/17 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/42 | 14/66 | 5/33 | 2/17 |
| InsomniaPsychiatric disorders | 14/42 | 21/66 | 9/33 | 6/17 |
| Dizziness (excl vertigo)Nervous system disorders | 13/42 | 18/66 | 4/33 | 3/17 |
| Oedema lower limbGeneral disorders | 9/42 | 19/66 | 8/33 | 5/17 |
| RigorsGeneral disorders | 11/42 | 14/66 | 5/33 | 2/17 |
| Age, Categorical(Participants) | V-DR | VDCR | V-DC | VDC-mod | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 27 | 42 | 21 | 11 | 101 |
| >=65 years | 15 | 24 | 12 | 6 | 57 |
| Age Continuous(years) | V-DR | VDCR | V-DC | VDC-mod | Total |
|---|---|---|---|---|---|
| Mean | 59.5 ± 8.76 | 60.9 ± 8.97 | 61.4 ± 8.32 | 59.6 ± 9.16 | 60.5 ± 8.75 |
| Sex: Female, Male(Participants) | V-DR | VDCR | V-DC | VDC-mod | Total |
|---|---|---|---|---|---|
| Female | 18 | 28 | 14 | 10 | 70 |
| Male | 24 | 38 | 19 | 7 | 88 |
| Region of Enrollment(participants) | V-DR | VDCR | V-DC | VDC-mod | Total |
|---|---|---|---|---|---|
| United States | 42 | 66 | 33 | 17 | 158 |
The record gives a start of Aug 2007, a primary completion of Oct 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2011, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Lenalidomide
Millennium Pharmaceuticals, Inc. →